Candel Therapeutics Shares Soar 11.34% on Earnings, Clinical Progress

Candel Therapeutics, Inc. (CADL) shares surged 11.34% in pre-market trading on April 24, 2025, reflecting a significant uptick in investor interest.

Candel Therapeutics recently reported its Q1 earnings, which contributed to a notable increase in its stock price. The company's market capitalization also saw a substantial rise, indicating strong investor confidence in its financial performance and future prospects.

In addition to the earnings report, Candel Therapeutics announced an oral presentation of its clinical-stage biopharmaceutical developments. This presentation highlighted the company's progress in developing multimodal biological immunotherapies, which are designed to enhance patient outcomes. The positive reception of this presentation further bolstered investor optimism.

Furthermore, the company's stock price target was raised to $25 from $20 by Canaccord, underscoring the growing bullish sentiment surrounding Candel Therapeutics. This price target adjustment reflects analysts' confidence in the company's potential for future growth and success in the biopharmaceutical sector.